Inclisiran: Additional Ph II ORION-1 data

Additional data from the double-blind, international Phase II ORION-1 trial in 497 patients with atherosclerotic cardiovascular disease or atherosclerotic cardiovascular disease-risk equivalents and elevated

Read the full 241 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE